News | October 30, 2014

Largest Clinical Experience on the Convergent Procedure Presented

Two hundred twenty-four patients treated for atrial fibrillation with 93 percent in sinus rhythm at one-year follow-up

October 30, 2014 — New physician experience for the Convergent Procedure in the treatment of persistent atrial fibrillation (AF) was presented during a podium talk at the Northeast Cardiothoracic Surgical Society 20th Annual Meeting held in East Madison, N.H. William M. Boedefeld II, M.D., of CVT Surgical Center in Baton Rouge, La., reported on 224 patients, 66 percent of whom had persistent or longstanding persistent AF and 34 percent who had paroxysmal AF. At one-year follow-up, 93 percent of patients were in sinus rhythm.

"The Convergent Procedure is our first-line treatment for AF patients with enlarged atria," stated Boedefeld. "For patients with enlarged atria where we may anticipate a second procedure with traditional catheter ablation, even in paroxysmal AF patients, we see the Convergent Procedure as the best opportunity for single-procedure results. The key clinical advantage is the ability to electrically silence the heart's posterior wall, where the majority of AF triggers are known to reside. We achieve this through a minimally invasive procedure, under direct visibility. Our electrophysiology partners can then complete the procedure in the same EP lab setting — our average total procedure time is 3.95 hours."

The multidisciplinary Convergent Procedure is performed as a single procedure in the electrophysiology lab. The epicardial lesions are created first under direct endoscopic visualization by a surgeon, through a 2 cm incision in the abdomen, with no chest incisions or ports. The endocardial lesions created by an electrophysiologist ensure lesion set completeness, and specialized EP mapping and diagnostics provide the checks and balances to ensure a comprehensive approach.

"The Convergent Procedure addresses the progressive nature of AF," said Kenneth C. Civello Jr., M.D., MPH, of Our Lady of the Lake Regional Medical Center in Baton Rouge, La. "Standardized, comprehensive ablation of the posterior wall can result in reverse remodeling where the overall atrial volume can be reduced, and function can improve. This allows us to use the Convergent Procedure for all patients with enlarged atria. Patients can then be provided customized care within a long-term disease management program."

For more information: www.fmolhs.org/ololrmc

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias
News | Ablation Systems | May 14, 2019
The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
Overlay Init